CV Sciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $16.0M | $16.2M | $20.0M | $24.4M | $53.7M | $48.2M |
| Cost of Revenue | $7.0M | $8.5M | $8.9M | $10.7M | $11.4M | $13.4M | $18.6M | $14.4M |
| Gross Profit | $6.8M | $7.2M | $7.1M | $5.6M | $8.6M | $11.0M | $35.1M | $33.9M |
| Gross Margin | 49.0% | 45.6% | 44.3% | 34.2% | 43.0% | 45.1% | 65.3% | 70.2% |
| Operating Expenses | ||||||||
| Research & Development | $122.0K | $118.0K | $151.0K | $307.0K | $1.2M | $2.9M | $5.9M | $1.9M |
| SG&A Expense | $7.6M | $9.2M | $9.7M | $12.1M | $25.9M | $30.7M | $46.5M | $21.7M |
| Operating Income | $-470.0K | $-2.2M | $3.4M | $-6.8M | $-18.4M | $-22.6M | $-17.2M | $10.2M |
| Operating Margin | -3.4% | -13.9% | 21.0% | -42.3% | -92.0% | -92.5% | -32.1% | 21.2% |
| Interest Expense | — | — | — | $600.0K | $38.0K | — | — | $153.0K |
| Pretax Income | $-949.0K | $-2.4M | $3.1M | $-8.3M | $-15.6M | $-22.6M | $-17.2M | $10.1M |
| Income Tax Expense | $9.0K | $-8.0K | $-6.0K | $-47.0K | $-87.0K | $-317.0K | $-615.0K | $93.0K |
| Net Income | $-958.0K | $-2.4M | $3.1M | $-8.2M | $-15.6M | $-22.3M | $-16.6M | $10.0M |
| Net Margin | -6.9% | -15.2% | 19.4% | -50.7% | -77.6% | -91.2% | -30.9% | 20.7% |
| EPS (Basic) | $-0.01 | $-0.01 | $0.02 | $-0.07 | $-0.14 | $-0.22 | $-0.17 | $0.11 |
| EPS (Diluted) | $-0.01 | $-0.01 | $0.02 | $-0.07 | $-0.14 | $-0.22 | $-0.17 | $0.09 |
| Shares Outstanding (Basic) | 184.3M | 175.6M | 154.0M | 138.0M | 107.8M | 99.9M | 97.9M | 91.9M |
| Shares Outstanding (Diluted) | 184.3M | 175.6M | 154.0M | 138.0M | 107.8M | 99.9M | 97.9M | 114.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |